MA31076B1 - Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine. - Google Patents

Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.

Info

Publication number
MA31076B1
MA31076B1 MA32040A MA32040A MA31076B1 MA 31076 B1 MA31076 B1 MA 31076B1 MA 32040 A MA32040 A MA 32040A MA 32040 A MA32040 A MA 32040A MA 31076 B1 MA31076 B1 MA 31076B1
Authority
MA
Morocco
Prior art keywords
isocinoline
substituted
cycloquine
derivatives
rho
Prior art date
Application number
MA32040A
Other languages
Arabic (ar)
English (en)
Inventor
Oliver Plettenburg
Katrin Lorenz
Jochen Goerlitzer
Matthias Löhn
Sandrine Biscarrat
Frédéric Jeannot
Olivier Duclot
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31076B1 publication Critical patent/MA31076B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

L'invention concerne des dérivés d'isoquinoline et d'isoquinolinone 6-substitués représentés par la formule (i), utilisés dans le traitement et/ou la prévention de maladies associées à la rho-kinase et/ou à la phosphorylation médiée par la rho-kinase de la phosphatase de la chaîne légère de la myosine, et des compositions contenant lesdits composés.
MA32040A 2006-12-27 2009-06-24 Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine. MA31076B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06026897 2006-12-27
PCT/EP2007/011169 WO2008077556A1 (fr) 2006-12-27 2007-12-19 Dérivés d'isoquinoline et d'isoquinolinone substitués par une cycloalkylamine

Publications (1)

Publication Number Publication Date
MA31076B1 true MA31076B1 (fr) 2010-01-04

Family

ID=38050127

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32040A MA31076B1 (fr) 2006-12-27 2009-06-24 Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.

Country Status (37)

Country Link
US (1) US8710077B2 (fr)
EP (1) EP2102164B1 (fr)
JP (1) JP5318779B2 (fr)
KR (1) KR101494452B1 (fr)
CN (1) CN101578266B (fr)
AR (1) AR064531A1 (fr)
AT (1) ATE490243T1 (fr)
AU (1) AU2007338412B2 (fr)
BR (1) BRPI0720859A2 (fr)
CA (1) CA2673922C (fr)
CL (1) CL2007003820A1 (fr)
CO (1) CO6210815A2 (fr)
CR (1) CR10811A (fr)
CY (1) CY1111323T1 (fr)
DE (1) DE602007010981D1 (fr)
DK (1) DK2102164T3 (fr)
EC (1) ECSP099468A (fr)
ES (1) ES2355534T3 (fr)
GT (1) GT200900183A (fr)
HR (1) HRP20100705T1 (fr)
MA (1) MA31076B1 (fr)
MX (1) MX2009005967A (fr)
MY (1) MY154767A (fr)
NI (1) NI200900111A (fr)
NO (1) NO20092488L (fr)
NZ (1) NZ577984A (fr)
PL (1) PL2102164T3 (fr)
PT (1) PT2102164E (fr)
RS (1) RS51655B (fr)
RU (1) RU2468011C2 (fr)
SI (1) SI2102164T1 (fr)
SV (1) SV2009003314A (fr)
TN (1) TN2009000274A1 (fr)
TW (1) TWI423803B (fr)
UY (1) UY30845A1 (fr)
WO (1) WO2008077556A1 (fr)
ZA (1) ZA200903555B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006008945D1 (de) 2005-06-28 2009-10-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho-kinase
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
SI1912949T1 (sl) 2005-07-26 2011-12-30 Sanofi Sa Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
DK1910333T3 (da) 2005-07-26 2013-08-19 Sanofi Sa Piperidinylsubstituerede isoquinolonderivater som RHO-kinaseinhibitorer
CA2664335C (fr) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Inhibiteurs de la rho-kinase
EP2114920A1 (fr) 2006-12-27 2009-11-11 Sanofi-Aventis Dérivés d'isoquinoline et d'isoquinolinone substitués
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
AU2007338411B2 (en) 2006-12-27 2012-08-23 Sanofi-Aventis Substituted isoquinolines and their use as Rho-kinase inhibitors
AU2007338406B2 (en) 2006-12-27 2012-08-09 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
ATE490243T1 (de) 2006-12-27 2010-12-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
CA2673917C (fr) 2006-12-27 2015-01-27 Sanofi-Aventis Derives d'isoquinolone substitues par une cycloalkylamine
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
SI2303845T1 (sl) * 2008-06-24 2013-12-31 Sanofi Bi- in policiklični substituirani izokinolin in izokinolinski derivati kot inhibitorji rho-kinaze
KR101638326B1 (ko) 2008-06-24 2016-07-12 사노피 Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논
ES2436531T3 (es) * 2008-06-24 2014-01-02 Sanofi Isoquinolinas e isoquinolinonas sustituidas en posición 6
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2755095A1 (fr) * 2009-03-09 2010-09-16 Surface Logix, Inc. Inhibiteurs de la rho kinase
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
CN103648499B (zh) * 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
KR20150130398A (ko) * 2013-03-14 2015-11-23 브리스톨-마이어스 스큅 컴퍼니 비시클로 [2.2.2] 산 gpr120 조절제
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
EP2968337B1 (fr) * 2013-03-15 2021-07-21 Celgene CAR LLC Composés hétéroaryle et utilisations associées
CN110396085B (zh) 2013-03-15 2024-11-15 爱尔康公司 联合治疗
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
PT3290407T (pt) 2013-10-18 2020-04-06 Celgene Quanticel Res Inc Inibidores de bromodomínio
JP6542794B2 (ja) 2013-12-12 2019-07-10 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー 二環式アルキル化合物、および合成
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR102401840B1 (ko) 2014-03-07 2022-05-25 리커리엄 아이피 홀딩스, 엘엘씨 프로펠란 유도체 및 합성
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
EP3376870B1 (fr) 2015-11-17 2021-08-11 Aerie Pharmaceuticals, Inc. Procédé de préparation d'inhibiteurs de kinase et de leurs intermédiaires
US20190060257A1 (en) * 2016-03-16 2019-02-28 Zeno Royalties & Milestones, LLC Analgesic compounds
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
BR112019020078A2 (pt) 2017-03-31 2020-04-28 Aerie Pharmaceuticals Inc compostos e composições farmacêuticas à base de arilciclopropil-amino-isoquinolinil amida e métodos de uso dos mesmos
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN117337267A (zh) * 2021-04-05 2024-01-02 达纳－法伯癌症研究所公司 适用于点击/取消点击应用的生物正交反应

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
HU178522B (en) * 1979-04-11 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing amino-isoquinoline derivatives
WO1992002476A1 (fr) 1990-07-31 1992-02-20 E.I. Du Pont De Nemours And Company Equilibrage catalytique d'halocarbones selectionnes
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
KR100576148B1 (ko) 1996-08-12 2006-05-03 미쯔비시 웰 파마 가부시키가이샤 Ｒｈｏ 키나아제 억제제를 함유하는　약제
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
US6362191B1 (en) 1997-08-29 2002-03-26 Zeneca Ltd. Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
US6784192B2 (en) 2000-01-20 2004-08-31 Eisai Co., Ltd. Piperidine compound and pharmaceutical composition thereof
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
JP2004502759A (ja) * 2000-07-12 2004-01-29 アクゾ・ノベル・エヌ・ベー アミノイソキノリン基を有するトロンビン阻害剤
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (fr) 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
EP1389194A2 (fr) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
WO2002100833A1 (fr) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (fr) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement des maladies a prions
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2004009555A1 (fr) * 2002-07-22 2004-01-29 Asahi Kasei Pharma Corporation Derive d'isoquinoline 5-substituee
EP1550660A1 (fr) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci
WO2004105757A2 (fr) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Utilisation des inhibiteurs de la rho kinase dans le traitement de l'anevrisme et de l'hypertrophie cardiaque
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2004276236B2 (en) 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US7691879B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
WO2005035516A1 (fr) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique fondu et utilisation correspondante
WO2005054202A1 (fr) 2003-11-25 2005-06-16 Eli Lilly And Company Derives de 7-phenyl-isoquinoline-5-sulfonylamino en tant qu'inhibiteurs de akt (proteine kinase b)
JP2005232175A (ja) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
WO2005074535A2 (fr) 2004-01-30 2005-08-18 Eisai Co., Ltd. Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
SI1912949T1 (sl) 2005-07-26 2011-12-30 Sanofi Sa Cikloheksilamin izokinolonski derivati kot inhibitorji Rho-kinaze
DK1910333T3 (da) 2005-07-26 2013-08-19 Sanofi Sa Piperidinylsubstituerede isoquinolonderivater som RHO-kinaseinhibitorer
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
AU2007338411B2 (en) 2006-12-27 2012-08-23 Sanofi-Aventis Substituted isoquinolines and their use as Rho-kinase inhibitors
ATE490243T1 (de) 2006-12-27 2010-12-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate

Also Published As

Publication number Publication date
ES2355534T8 (es) 2011-05-09
ECSP099468A (es) 2009-07-31
AR064531A1 (es) 2009-04-08
CY1111323T1 (el) 2015-08-05
ATE490243T1 (de) 2010-12-15
ZA200903555B (en) 2010-04-28
TWI423803B (zh) 2014-01-21
CN101578266A (zh) 2009-11-11
NI200900111A (es) 2010-01-15
CN101578266B (zh) 2013-10-30
RS51655B (sr) 2011-10-31
SV2009003314A (es) 2010-02-05
HK1138585A1 (en) 2010-08-27
TW200843769A (en) 2008-11-16
WO2008077556A1 (fr) 2008-07-03
CL2007003820A1 (es) 2008-08-01
RU2468011C2 (ru) 2012-11-27
AU2007338412B2 (en) 2013-03-14
BRPI0720859A2 (pt) 2014-03-25
KR20090094110A (ko) 2009-09-03
CR10811A (es) 2009-08-12
CA2673922A1 (fr) 2008-07-03
HRP20100705T1 (hr) 2011-01-31
NO20092488L (no) 2009-09-22
CO6210815A2 (es) 2010-10-20
AU2007338412A1 (en) 2008-07-03
US20100056553A1 (en) 2010-03-04
NZ577984A (en) 2011-03-31
RU2009128652A (ru) 2011-02-10
GT200900183A (es) 2010-07-02
SI2102164T1 (sl) 2011-03-31
MX2009005967A (es) 2009-06-15
KR101494452B1 (ko) 2015-02-16
JP2010514721A (ja) 2010-05-06
EP2102164B1 (fr) 2010-12-01
TN2009000274A1 (en) 2010-10-18
PL2102164T3 (pl) 2011-05-31
ES2355534T3 (es) 2011-03-28
CA2673922C (fr) 2015-09-29
MY154767A (en) 2015-07-15
EP2102164A1 (fr) 2009-09-23
US8710077B2 (en) 2014-04-29
UY30845A1 (es) 2008-07-31
DK2102164T3 (da) 2011-03-21
DE602007010981D1 (de) 2011-01-13
PT2102164E (pt) 2011-01-21
JP5318779B2 (ja) 2013-10-16

Similar Documents

Publication Publication Date Title
MA31076B1 (fr) Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.
MA31024B1 (fr) Nouveaux derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31022B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31075B1 (fr) Dérivés d'isoquinolone substitués par une cycloalkylamine.
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA31023B1 (fr) Derives de l'isoquinolone et de l'isoquinoleinone substituees par une cycloalkylamine
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
MA29639B1 (fr) Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase.
ATE554072T1 (de) Cycloalkylaminsubstituierte isochinolinderivate
MA32399B1 (fr) Isoquinoléines et isoquinoléinones 6-substituées.
MA32401B1 (fr) Derives d'isoquinoleine et d'isoquinoleinone substitues bi-et polycycliques
UY29698A1 (es) Derivados de ciclohexilaminisoquinolona